Microplastics in Your Arteries: What the 2024 Carotid Plaque Study Really Showed
Asare B. Christian, MD, MPH · 2026-11-13
Direct Answer
In 2024, researchers found microplastic and nanoplastic particles inside carotid artery plaque removed during surgery, and patients whose plaque contained plastic particles had a higher rate of heart attack, stroke, and death over roughly three years. This is a real and concerning observation, but it is an association, not proof that plastics caused those events.
What the Study Actually Measured
Investigators in Italy collected carotid plaque from 257 patients undergoing carotid endarterectomy, surgery to remove plaque narrowing the artery. They analyzed the tissue with pyrolysis gas chromatography mass spectrometry and electron microscopy, then followed patients for a mean of about 34 months.
Three findings matter.
First, polyethylene was detectable in the plaque of 150 patients, about 58 percent, and polyvinyl chloride in 31 patients. Second, particles were visible inside the plaque itself, within macrophages, not simply on the surface. Third, the composite endpoint of heart attack, stroke, or death from any cause occurred in 20 percent of patients with detectable plastic particles compared with 7.5 percent of those without.
That last number is the one that traveled through headlines. It is also the number most often quoted without its context.
Why This Is Not Proof of Causation
The study was observational. Patients were not assigned to have plastic in their arteries. Something else that raises plaque burden, inflammation, or metabolic risk could plausibly raise both plastic accumulation and cardiovascular events.
The sample was small, 257 people, all of whom already had disease severe enough to require surgery. That is a very selected group. The confidence interval around the effect estimate was wide.
There is also a measurement problem in this field. Contamination is a genuine methodological hazard: plastic is everywhere in a laboratory, and distinguishing particles that were in the tissue from particles introduced during handling requires rigorous controls. The Italian group used multiple methods and reported contamination controls, which is part of why the paper was taken seriously. But replication by independent groups is what turns a striking finding into an established one.
What the Broader Evidence Base Looks Like
Microplastics have now been detected in human blood, lung tissue, placental tissue, testis, liver, and bone marrow. Detection studies are accumulating faster than health outcome studies, and that imbalance is exactly why the field is confusing to read as a patient.
The honest summary in 2026: human exposure is universal, internal presence is documented, and health consequences in humans remain incompletely characterized. Laboratory work shows plausible mechanisms, including macrophage activation, oxidative stress, and chronic low-grade inflammation. Plausible mechanism plus detected exposure is a reason for concern and further study. It is not the same as a demonstrated clinical effect size.
What This Means Clinically
I do not have a test that measures your arterial plastic burden, and no such test is validated for clinical use. I cannot tell a patient their microplastic exposure is high or low. Anyone selling that certainty is ahead of the science.
What I can say is that the exposures associated with higher particle burden overlap heavily with the exposures we already treat: metabolic dysfunction, chronic inflammation, air pollution, and diet quality. Reducing those is not a compromise position. It is the intervention with actual outcome data behind it.
There is also a reasonable case for practical reduction where the cost is low and the downside is zero: avoid heating food in plastic, favor glass and stainless steel for storage, filter drinking water, ventilate cooking spaces, and choose fewer synthetic textiles for close-contact items. None of these has been proven to lower cardiovascular events. All of them are harmless and some reduce exposures that are independently worth reducing, such as phthalates and bisphenol compounds.
Limitations Patients Should Hear
We do not know the dose-response relationship in humans. We do not know whether particle size, polymer type, or duration of exposure matters most. We do not have a single intervention trial showing that lowering internal plastic burden changes any clinical outcome, because we do not yet have a reliable way to lower it measurably.
The 2024 study should be read as a signal warranting investigation, and the authors framed it that way. It became a headline that outran its own design.
Frequently Asked Questions
Should I get tested for microplastics? There is no validated clinical test. Research assays exist in specialized laboratories and are not actionable for an individual patient.
Can I avoid microplastics entirely? No. They are in air, water, soil, and food supply at low levels. Reduction, not elimination, is the realistic frame.
Does plasma exchange remove microplastics? Not selectively. Some circulating particles may be removed, but there is no evidence that this changes any health outcome, and no protocol exists for it.
Is bottled water worse than tap? Studies have found higher particle counts in bottled water than tap, though both are low and the clinical significance is unknown. Filtered tap water is a reasonable default.
References
- Marfella R, et al. Microplastics and nanoplastics in atheromas and cardiovascular events. N Engl J Med. 2024;390:900-910.
- Leslie HA, et al. Discovery and quantification of plastic particle pollution in human blood. Environ Int. 2022.
- Ragusa A, et al. Plasticenta: first evidence of microplastics in human placenta. Environ Int. 2021.
- World Health Organization. Dietary and inhalation exposure to nano- and microplastic particles. 2022.
Educational information only. This article is a draft for physician review and is not individualized medical advice.